ALK inhibitors(Anaplastic lymphoma kinase inhibitors), ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors), c-Met inhibitors(Hepatocyte growth factor receptor inhibitors)

Therapeutic Areas

NeoplasmsRespiratory DiseasesSkin and Musculoskeletal Diseases

Active Indication

ALK positive Non-Small Cell Lung CancerMelanomaSmall Cell Lung Cancer

Inactive Indication

Advanced Malignant Solid NeoplasmBrain metastasesmetastatic non-small cell lung cancer+ [1]

Originator Organization

Xcovery, Inc.

Active Organization

Betta Pharmaceuticals Co., Ltd.

Xcovery Holding, Inc.

Inactive Organization

MedImmune LLC

Drug Highest PhaseApproved

First Approval Date

CN (17 Nov 2020),

ALK positive Non-Small Cell Lung Cancer

RegulationConditional marketing approval (CN), Priority Review (CN)

Structure

Molecular FormulaC26H29Cl4FN6O3

InChIKeyIERUINQRGJAECT-ISUJJMBGSA-N

CAS Registry2137030-98-7

Clinical Trials associated with Ensartinib Hydrochloride

NCT06563999 / Not yet recruitingPhase 2IIT

Neoadjuvant Umbrella Trial Directed by Next Generation Sequencing for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations (Without EGFR Sensitizing Mutations)

This umbrella trial directed by next generation sequencing (NGS) includes patients with treatment-naive unresectable stage III non-small-cell lung cancer (NSCLC). The aim of the umbrella study is to evaluate the efficacy of induction NGS-directed targeted therapies followed by surgery for stage III NSCLC patients whose tumor harbors a rare mutation.

Start Date01 Dec 2024

Sponsor / Collaborator

Sun Yat-Sen University

NCT06492525 / Not yet recruitingPhase 1

A Phase 1, Open-label, 2-period, Fixed Sequence, Cross-over Study To Investigate The Effect Of Multiple Doses Of Rifampicin Or Itraconazole On The Pharmacokinetics Of Single Dose Ensartinib In Healthy Volunteers.

The purpose of this study is to estimate the effect of rifampicin or itraconazole on the single dose PK of ensartinib.

Start Date01 Jul 2024

Sponsor / Collaborator

Betta Pharmaceuticals Co., Ltd.

ChiCTR2300070192 / SuspendedPhase 2IIT

Efficacy and safety of adjuvant therapy of ensartinib in ALK-positive stage II-IIIB non-small cell lung cancer:a prospective, multicenter, single-arm phase II trial

Start Date01 May 2023

Sponsor / Collaborator-

100 Clinical Results associated with Ensartinib Hydrochloride

100 Translational Medicine associated with Ensartinib Hydrochloride

100 Patents (Medical) associated with Ensartinib Hydrochloride

112

Literatures (Medical) associated with Ensartinib Hydrochloride

01 Dec 2024·Asia-Pacific Journal of Clinical Oncology

Ensartinib in the treatment of anaplastic lymphoma kinase‐positive locally advanced or metastatic patients with lung squamous or adenosquamous carcinoma: A real‐world, retrospective study

Article

Author: Ji, Dong ; Yang, Min ; Yuan, Xiaobin ; Wang, Yang ; Ma, Yongbin ; Ding, Lieming ; Yun, Yu ; Chen, Hui ; Shen, Zhilin ; Wu, Pengxiang

Abstract:

Aim:

To report the efficacy and safety of ensartinib, an anaplastic lymphoma kinase (ALK) inhibitor, in treating patients with ALK‐positive advanced lung squamous cell carcinoma (LUSC) or lung adenosquamous carcinoma (LASC) in China.

Methods:

This retrospective study analyzed data for 36 advanced‐stage patients with ALK‐positive LUSC (cohort A) and 13 patients with ALK‐positive LASC (cohort B) between December 16, 2020 and December 16, 2021. All patients received once‐daily ensartinib 225 mg. Outcome analysis included the demographic characteristics, tumor response, progression‐free survival (PFS), and treatment‐related adverse events (TRAE).

Results:

Among the 49 patients, the majority were under 65 years old (73.5%), non‐smokers (85.7%), had an Eastern Cooperative Oncology Group Performance Status of 0–1 (77.6%), and were at stage IV (71.4%). All patients were included in the efficacy and safety analysis. Seven PFS events were reported in cohort A while no patients experienced PFS events in cohort B. The median PFS was not estimable for both cohorts. In cohort A, the objective response rate (ORR) was 63.9%, and the disease control rate (DCR) was 83.3%. In the cohort B, the ORR was 76.9% and the DCR was 100.0%. Rash was the only TRAE reported in the cohort A (8.3%) and cohort B (23.1%). No patients had grade 3 or higher TRAE.

Conclusion:

Ensartinib has been tentatively proven favorable efficacy and tolerability in the treatment of patients with ALK‐positive advanced LUSC or LASC in the real‐world. However, confirmatory studies are still needed in larger sample sizes.

01 Oct 2024·Heliyon

Small intestinal metastasis in a lung adenocarcinoma patient with concurrent EML4-ALK V3 and TP53 mutations after distinct responses to tyrosine kinase inhibitors: A case report

Article

Author: Zhang, Yongqian ; Ma, Wenhua ; Guo, Ying ; Zhao, Min ; Liu, Zhai ; Lv, Hengxu ; Zhao, Yingchun ; Wang, Qian ; Zhu, Lingling ; Guo, Yan

Background:

Although anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) have improved the survival rates of lung cancer patients with ALK fusion mutations, their effectiveness varies significantly across different subtypes. We report a case of small intestine metastasis in a lung adenocarcinoma patient with co-occurring echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion variant 3 (V3) and tumor protein 53 (TP53) mutations after distinct responses to ALK-TKIs.

Case presentation:

A 45-year-old woman was diagnosed with stage IV lung adenocarcinoma with brain metastasis. Next-generation sequencing revealed EML4-ALK V3 and TP53 co-mutations. After the initial treatment with ensartinib, the patient experienced intracranial disease progression. Radiation therapy (RT) was then administered. Despite good response to RT for the intracranial disease, the primary tumor enlarged. Thus, the patient was treated with oral ensartinib concurrent with chemotherapy, with a partial response in both the primary tumor and intracranial metastases. However, after three cycles of treatment, the patient discontinued chemotherapy because of acute kidney injury. Subsequent thoracic RT resulted in a partial response of the primary tumor; however, new brain and bone metastases were detected, prompting a switch to lorlatinib. The patient developed symptoms of intestinal obstruction 14 months after the initial diagnosis. Surgical intervention revealed a poorly differentiated metastatic lung adenocarcinoma of the upper jejunum. Genetic testing confirmed EML4-ALK V3 and TP53 co-mutations and high expression of programmed cell death-ligand 1. Despite pembrolizumab treatment, the patient's condition deteriorated, and she passed away.

Conclusion:

We reported a rare case of small intestinal metastasis in a lung adenocarcinoma patient with concurrent EML4-ALK V3/TP53 mutations after distinct responses to ALK-TKIs in different lesions. Our findings revealed heterogeneity in ALK mutations and responses to ALK-TKIs, necessitating the close monitoring of genetic subtypes and associated mutations for tailored treatment strategies. Maintaining a heightened awareness of potential intestinal metastasis and vigilance in monitoring intestinal symptoms and abdominal metastases are pivotal for managing advanced lung adenocarcinoma.

01 Sep 2024·Asian Journal of Surgery

Ensartinib rapidly relieves symptoms in ALK-positive patients with brain metastases

Letter

Author: Zheng, Yan ; Fang, Wenzheng ; Xu, Hongyan ; Chen, Tingting

News (Medical) associated with Ensartinib Hydrochloride

06 Jun 2024

·www.biospace.com

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and Opdivo for Bristol Myers Squibb CEL-SCI’s Multikine immunotherapy improves the 5-year survival of head and neck cancer patients to 73% compared to 45% in controls and cuts the 5-year risk of death by 50% FDA has given CEL-SCI the go-ahead to commence a confirmatory Registration Study for Multikine for the target population in head and neck cancer Dr. Selvaggi will be supporting CEL-SCI to bring Multikine to patients through a confirmatory registrational path that has been agreed with regulatory authorities and that has a potential for cure VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM) today announced Dr. Giovanni Selvaggi, an oncology key opinion leader instrumental in successfully bringing several drugs to market has joined CEL-SCI as a Clinical Advisor. Dr. Selvaggi joins CEL-SCI as the Company recently received its go-ahead from the U.S. Food and Drug Administration (FDA) for its confirmatory Registration Study of Multikine* in the treatment of head and neck cancer. This press release features multimedia. View the full release here: (Graphic: Business Wire) Multikine is the first investigational pre-surgical cancer drug in newly diagnosed head and neck cancer. Multikine is a copy of the pro-inflammatory cytokine immune response human bodies produce every day and is designed to empower a person’s intact immune system cells to attack their own cancer. Patients are treated with Multikine right after diagnosis, before any other standard of care treatment (surgery and radiation therapy) since that is when the immune system is strongest. There is robust safety and efficacy data from 750 patients who have been treated with Multikine. Based on the following efficacy data, the FDA has agreed to CEL-SCI’s 212-person Registration Study to confirm the findings for regulatory approval: No safety signals vs standard of care 73% survival for Multikine vs 45% in the control arm at 5 years Statistically significant p = 0.0015 5-year risk of death cut in half from 55% to 27% (Hazard ratio = 0.35 (95% CIs [0.19, 0.66]) More detailed results may be viewed here: LINK Dr. Selvaggi is a US-based drug developer, cancer researcher, and strategic advisor to big pharma and early-to-late stage biotech companies. He is currently Chief Medical Officer at Xcovery Holdings, where he manages an ongoing New Drug Application with the FDA for ensartinib, an ALK-TKI for non-small cell lung cancer (NSCLC). He is also a Clinical Consultant to Tubulis GmBH for a first-in-class ADC program in solid tumors, and Clinical Strategy Senior Advisor to Alira Health. He formerly served as Medical Director, Cancer Immunotherapy, in the MAGE-A3 lung cancer vaccine program at GSK. Later, Dr. Selvaggi played an instrumental role in the successful development and approval of ceritinib (Zykadia) in ALK-translocated NSCLC at Novartis. At Oncolytics he was VP of Clinical Development. Most recently, Dr. Selvaggi was part of the immunotherapy team at Bristol-Myers Squibb, serving as a program lead in thoracic malignancies, with a focus on SCLC and mesothelioma, leading to the approval of nivolumab (Opdivo) in third line small cell lung cancer. Dr. Selvaggi received his medical degree at the University of Torino School of Medicine, in Torino, Italy, and served as staff physician of thoracic oncology at the University Hospital in Torino, participating in several clinical trials in lung cancer and mesothelioma over a span of 20 years. Dr. Selvaggi commented, “Multikine is a first in class immunotherapy that has demonstrated to meaningfully and safely prolong survival in a selected orphan population of newly diagnosed head and neck cancer. The importance of tackling cancer at the earliest stages to guarantee the most relevant impact in patients’ lives is undeniable, especially in head and neck cancer which has no approved therapeutic options before surgery. I am fully committed to supporting CEL-SCI leadership to bring this asset to patients through an expedited registrational path that has been agreed with regulatory authorities and that has a potential for cure.” “Dr. Selvaggi has a passion for bringing cancer drugs to market to save lives and lead clinical research toward a cure for cancer. We are excited to have him join CEL-SCI as a Clinical Advisor at this pivotal point for Multikine which is set to commence a confirmatory FDA Registration Study,” stated CEL-SCI CEO, Geert Kersten. “The data on Multikine is excellent, and as we proceed with and wrap up this final study, Dr. Selvaggi’s experience and successful track record in navigating late-stage development, clinical trials, and the regulatory approval process will be hugely valuable for us.” Dr. Selvaggi joins several other top-tier physician consultants and head and neck cancer key opinion leaders who are advisors to CEL-SCI. About CEL-SCI Corporation CEL-SCI believes that boosting a patient’s immune system while it is still intact should provide the greatest possible impact on survival. Multikine is designed to help the immune system "target" the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, has been dosed in over 750 patients and received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck. Multikine significantly extended life in its target patient population demonstrating a 73% survival rate with Multikine vs. only 45% without at 5 years after treatment. Based on this very strong data, the FDA agreed to CEL-SCI’s target patient selection criteria and gave the go-ahead to conduct a small, focused, confirmatory Registration Study which will enroll 212 patients. CEL-SCI will enroll newly diagnosed advanced primary head and neck cancer patients with no lymph node involvement (determined via PET scan) and with low PD-L1 tumor expression (determined via biopsy), representing over 100,000 patients annually. The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such statements include, but are not limited to, statements about the terms, expected proceeds, use of proceeds and closing of the offering. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2023. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. * Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy. This proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. View source version on businesswire.com: Contacts Gavin de Windt CEL-SCI Corporation (703) 506-9460 Source: CEL-SCI Corporation Smart Multimedia Gallery Photo (Graphic: Business Wire) Logo View this news release and multimedia online at:

ImmunotherapyVaccineExecutive ChangeOrphan DrugClinical Study

13 Mar 2024

·www.businesswire.com

U.S. Food and Drug Administration (FDA) Has Accepted the New Drug Application (NDA) for Ensartinib

MIAMI--( BUSINESS WIRE )-- Xcovery Holdings, Inc. , an oncology focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for ensartinib, an Anaplastic Lymphoma Kinase (ALK) inhibitor for the treatment of adult patients with metastatic ALK-positive non-small cell lung cancer (NSCLC). The filing is based on the results of the eXalt3, a randomized global phase III study designed to evaluate the efficacy and safety of ensartinib vs crizotinib in the first-line treatment of ALK-positive NSCLC. The FDA granted the application Standard Review and assigned a Prescription Drug User Fee Act (PDUFA) goal date of December 28, 2024. “The FDA’s acceptance of this NDA represents a key milestone for Xcovery in its mission to bring ensartinib as a novel and distinct first-line therapeutic option to ALK-positive NSCLC patients,” said Giovanni Selvaggi, M.D., Chief Medical Officer of Xcovery. “We will continue to work closely with the agency during the review period. This achievement is a testament to our patient-centric vision and has been made possible by the dedication and skills of the entire Xcovery team and stakeholders, with the constant support of the patients, their families and investigators in our clinical trials globally.” Ensartinib is a next generation ALK inhibitor jointly developed by Xcovery and Betta Pharmaceuticals. In the clinical trials, the drug has demonstrated robust and durable responses in ALK-positive NSCLC patients (both systemically and in the brain), with an extensively studied and well manageable safety profile. The results of the eXalt3 were originally published in JAMA Oncology in September 2021. About Xcovery Xcovery is a pharmaceutical company working to improve the lives of patients with cancer by discovering and developing small molecules that precisely target cancer growth mechanisms. Xcovery is developing a pipeline of drugs targeting a wide range of advanced solid tumors with a focus on lung cancer. For more information, visit www.xcovery.com. Forward‐Looking Statements This press release contains forward‐looking statements that are based on company management’s current beliefs and expectations and are subject to currently unknown information, risks and circumstances and actual results may vary from what is being currently projected.

NDAPhase 3Priority ReviewClinical Result

04 Sep 2023

·www.outsourcing-pharma.com

Roche’s Alecensa smashes phase 3 as adjuvant therapy for lung cancer

Lung cancer is one of the leading causes of cancer deaths globally, with NSCLC being one of the most common forms of the disease. Additionally, many early lung cancer cases recur after surgery, despite modern treatment approaches including adjuvant chemotherapy and immunotherapy. Alecensa is a small molecule drug designed to block variations of the protein anaplastic lymphoma kinase (ALK), which occur in around 5% of NSCLC cases . The drug is already approved by the U.S. Food and Drug Administration (FDA) as a first-line treatment for ALK-positive, metastatic NSCLC. Roche is aiming to develop the drug in earlier stages of the disease as an adjuvant therapy following surgical removal of the tumor. In the trial, dubbed ALINA, Alecensa was compared with platinum-based chemotherapy in 257 patients with resected ALK-positive NSCLC. According to a pre-planned interim analysis, Alecensa’s improvement in disease-free survival met the trial’s primary endpoint, though the overall survival results were not ready to call. Roche also found no unexpected safety findings in the trial. “Alecensa has transformed outcomes for people with advanced ALK-positive NSCLC, and now these strong results provide evidence for the first time that this medicine could also play a pivotal role in early-stage disease where there is significant unmet need,” said Roche’s chief medical officer and head of global product development, Levi Garraway, in a public statement. “If approved, Alecensa has the potential to treat cancer before it has spread in a setting where treatment can increase the chances of cure, which is our ultimate goal at Roche. We look forward to sharing these data with regulatory authorities in hopes of bringing this to patients as quickly as possible.” googletag.cmd.push(function () { googletag.display('text-ad1'); }); Alecensa is one of several ALK inhibitors in the cancer treatment market. The first to be approved by the FDA for metastatic NSCLC was crizotinib in 2011. And other ALK inhibitors such as Pfizer's lorlatinib and Betta Pharmaceuticals’ ensartinib have emerged since Alecensa was first approved in 2015. If its development as an adjuvant proceeds to plan, Alecensa could become the first approved ALK inhibitor for early-stage ALK-positive lung cancer. While ALK inhibitors can be effective treatments for NSCLC, the cancer can develop resistance to these drugs . This is leading to the development of treatment combinations with other therapies to prevent resistance. For example, Alecensa showed promise in combination with the antibody drug bevacizumab in a phase 2 trial in patients with advanced ALK-positive NSCLC.

Clinical ResultDrug ApprovalPhase 3ImmunotherapyPhase 2

100 Deals associated with Ensartinib Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D11356	-	L01XE	DB14860

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
ALK positive Non-Small Cell Lung Cancer	CN	Betta Pharmaceuticals Co., Ltd.	17 Nov 2020

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Brain metastases	Phase 2	CN	Betta Pharmaceuticals Co., Ltd.	21 Mar 2019
Reactive oxygen species 1 positive non-small cell lung cancer	Phase 2	CN	Betta Pharmaceuticals Co., Ltd.	29 May 2018
Melanoma	Phase 2	US	Xcovery Holding, Inc.	10 Jan 2018
Advanced Malignant Solid Neoplasm	Phase 2	US	Xcovery Holding, Inc.	01 Jun 2012
Lung Cancer	Phase 1	CN	Betta Pharmaceuticals Co., Ltd.	11 Jun 2018
Small Cell Lung Cancer	Phase 1	CN	Betta Pharmaceuticals Co., Ltd.	07 Mar 2017
metastatic non-small cell lung cancer	Phase 1	CN	Betta Pharmaceuticals Co., Ltd.	06 Mar 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ChiCTR2100048767 (WCLC2024) Manual	Phase 2	MET Exon 14 Skipping Mutation Non-small Cell Lung Cancer MET Exon 14 Skipping	30	Ensartinib 225 mg	vyyjrkdwrb(kwiqwoqeqb) = vxwsyxrxcg ajgueihcvl (iqdqazyhde, 36.1% - 69.8) View more	Positive	10 Sep 2024
NCT03215693 (Literature) Manual	Phase 2	ALK positive Non-Small Cell Lung Cancer ALK Positive \| TP53 Mutation	180	Ensartinib 225 mg	fjsjjiyifo(dvtzasutdn) = ltqnzbqwpb syqqxluetr (qmuyzhgbix, 29.3 - 53.2) View more	Positive	29 Feb 2024
NCT02959619 (Pubmed)	Phase 1	ALK positive Non-Small Cell Lung Cancer	48	Ensartinib	wvwugistae(gpvzadayfd) = 4.2% fxhqsrwgnq (aytgcqigwu ) View more	-	01 Dec 2022
WCLC2022	Not Applicable	-	-	Crizotinib	gxuzfbahir(vrggietfsw) = ezmcdesdrb tgvopthmfi (dpemgyecok )	-	06 Aug 2022
				Alectinib	gxuzfbahir(vrggietfsw) = xexcwurtjt tgvopthmfi (dpemgyecok )
NCT03215693 (WCLC2022)	Phase 2	-	-	Ensartinib (ALK Fusion Subtype Variant 1 (V1))	viyngpskwq(uygxeingbz) = owqtlqoumd disjzaxhvw (spszitrkqu ) View more	-	06 Aug 2022
				Ensartinib (ALK Fusion Subtype Variant 3 (V3))	viyngpskwq(uygxeingbz) = giyhatqtar disjzaxhvw (spszitrkqu ) View more
NCT03608007 (Pubmed) Manual	Phase 2	Reactive oxygen species 1 positive non-small cell lung cancer ROS1 Positive	59	Ensartinib	yltdurwhuv(wtzaggginz) = ctfuytgkxh qzhuvlsiga (tvktyltird, 13.8 - 44.1) View more	Positive	01 Nov 2021
NCT02767804 (eXalt3, Pubmed \| JAMA Oncol) Manual	Phase 3	ALK positive Non-Small Cell Lung Cancer First line ALK Positive	290	Ensartinib Hydrochloride	nkbfyhqtgh(ljkgwbypue) = mwnxwvxett yyjqmqwyjx (akpzzkicie ) View more	Superior	01 Nov 2021
				Crizotinib	nkbfyhqtgh(ljkgwbypue) = apvsyntchq yyjqmqwyjx (akpzzkicie ) View more
WCLC2021	Not Applicable	-	178	Ensartinib (ALK-EML4 V1 subtype)	duysvdzmio(ldmmnbnxji) = htpozlxtjl phcwzlmmtm (xrzybjnwok )	-	08 Sep 2021
				Ensartinib (ALK-EML4 V3 subtype)	duysvdzmio(ldmmnbnxji) = kgpalufypj phcwzlmmtm (xrzybjnwok )
NCT02767804 (eXalt3, WCLC2021)	Phase 3	ALK positive Lung Cancer First line	290	Ensartinib	laxgqmuhtb(hrubcqylcb) = yjvlskhkfr sntvxcbdup (bqxoylncvr )	-	28 Jan 2021
				Crizotinib	laxgqmuhtb(hrubcqylcb) = mcfifrjoem sntvxcbdup (bqxoylncvr )
NCT03804541 (Pubmed \| Cancer Chemother Pharmacol)	Phase 1	-	6	Ensartinib 200 mg/100 μCi	yolghladfg(yjuibavbyy) = oglhkyzocw epptwctxlp (jsaqesqutx ) View more	-	01 Dec 2020

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis